Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 6/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585797 | 0.86 | KDM4E (0.47) | MAOBMEN1KMT2AMRGPRX4NR1H4 | |
| SCHEMBL5585550 | 0.83 | MAOB (0.41) | MAOBMEN1SLC26A4KMT2AF2RL3 | |
| SCHEMBL5585511 | 0.82 | MAOB (0.41) | MAOBMEN1SLC26A4KMT2AF2RL3 | |
| SCHEMBL5585479 | 0.80 | MAOB (0.41) | MAOBMEN1SLC26A4KMT2AF2RL3 | |
| SCHEMBL5585892 | 0.75 | NPC1 (0.49) | MAOBMEN1KMT2AMRGPRX4RXRA | |
| SCHEMBL5999790 | 0.75 | MAOB (0.42) | MAOBMEN1SLC26A4KMT2AF2RL3 | |
| SCHEMBL5585686 | 0.74 | KMT2A (0.47) | MAOBMEN1KMT2AMRGPRX4NR1H4 | |
| SCHEMBL5585713 | 0.72 | LPAR1 (0.37) | MAOBF2RL3MAOAFFAR1 | |
| SCHEMBL5585391 | 0.72 | NR4A2 (0.42) | MAOBF2RL3RXRARXRB | |
| SCHEMBL5585379 | 0.72 | F2RL3 (0.38) | MEN1KMT2AF2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | MAOB 1036/4885MEN1 3299/4885SLC26A4 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.